1. Cho K, Shih IM: Ovarian cancer. Ann Rev Pathol 4:287-313, 2009.
2. Scully RE: International Histological Classification of Tumors: Histological Typing of Ovarian Tumors. Geneva: World Health Organization, 1999, pp 3-44.
3. Tavassoli FA, Deville P: Tumours of the Breast and Female Genital Organs: World Health Organization Classification of Tumours. Lyon: IARC Press, 2003, pp 117-145.
4. Singer G, Kurman RJ, Chang H-W, et al: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160:12231228, 2002.
5. Ortiz BH, Ailawadi M, Colitti C, et al: Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61:7264-7267, 2001.
6. Bell DA, Scully RE: Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 73:1859-1864, 1994.
7. Caduff RF, Svoboda-Newman SM, Ferguson AW, et al: Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 23:323-328, 1999.
8. Dubeau L: Ovarian cancer. In Scriver CR, Beaudet AL, Sly WS (eds): The Metabolic and Molecular Bases of Inherited Disease. Toronto: McGraw-Hill, 2001, pp 1091-1096.
9. Burks RT, Sherman ME, Kurman RJ: Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20:13191330, 1996.
10. Riopel MA, Ronnett BM, Kurman RJ: Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23:617-635, 1999.
11. Seidman JD, Kurman RJ: Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinico-pathologic study of 65 advanced stage cases. Am J Surg Pathol 20:1331-1345, 1996.
12. Sehdev AES, Sehdev PS, Kurman RJ: Noninvasive and invasive micropapillary serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 27:725-736, 2003.
13. Okuda T, Otsuka J, Sekizawa A, et al: p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 88:318-325, 2003.
14. Modesitt SC, Tortolero-Luna G, Robinson JB, et al: Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 100:788-795, 2002.
15. Horiuchi A, Itoh K, Shimizu M, et al: Toward understanding the natural history of ovarian carcinoma development: a clinico-pathological approach. Gynecol Oncol 88:309-317, 2003.
16. Masuda A, Takeda A, Fukami H, et al: Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer 60:1697-2703, 1987.
17. Moritani S, Moriya T, Kushima R, et al: Ovarian carcinoma recurring as carcinosarcoma. Pathol Int 51:380-384, 2001.
18. Dehari R, Kurman RJ, Logani S, et al: The development of highgrade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma— a morphologic and molecular genetic analysis. Am J Surg Pathol, 31:1007-1012, 2007.
19. Peyssonnaux C, Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53-62, 2001.
20. Singer G, Oldt R, III, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003.
21. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
22. Rajagopalan H, Bardelli A, Lengauer C, et al: RAF/RAS onco-genes and mismatch-repair status. Nature 418:934, 2002.
23. Cheng EJ, Kurman RJ, Wang M, et al: Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 84:778-784, 2004.
24. Chan W-Y, Cheung K-K, Schorge JO, et al: Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156:409-417, 2000.
25. Kohler MF, Marks JR, Wiseman RW, et al: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519, 1993.
26. Kupryjanczyk J, Thor AD, Beauchamp R, et al: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961^965, 1993.
27. Berchuck A, Carney M: Human ovarian cancer of the surface epithelium. Biochem Pharmacol 54:541-544, 1997.
28. Wen WH, Reles A, Runnebaum IB, et al: p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 18:29-41, 1999.
29. Shelling AN, Cooke I, Ganesan TS: The genetic analysis of ovarian cancer. Br J Cancer 72:521-527, 1995.
30. Pothuri B, Leitao M, Barakat R, et al: Genetic analysis of ovarian carcinoma histogenesis. Society of Gynecologic Oncologists 32nd Annual Meeting. Gynecol Oncol (Abstract) 80, 2001.
31. Gallardo A, Matias-Guiu X, Lagarda H, et al: Malignant mulle-rian mixed tumor arising from ovarian serous carcinoma: a clini-
copathologic and molecular study of two cases. Int J Gynecol Pathol 21:268-272, 2002.
32. Kounelis S, Jones MW, Papadaki H, et al: Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 29:82-87, 1998.
33. Abeln EC, Smit VT, Wessels JW, et al: Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 183:424^31, 1997.
34. Sreenan JJ, Hart WR: Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19:666674, 1995.
35. Singer G, Rebmann V, Chen YC, et al: HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9:44604464, 2003.
36. Urosevic M, Kurrer MO, Kamarashev J, et al: Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159:817-824, 2001.
37. Urosevic M, Willers J, Mueller B, et al: HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99:609-617, 2002.
38. Chen YC, Pohl G, Wang TL, et al: Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 65:331-337, 2005.
39. Shih YC, Kerr J, Hurst TG, et al: No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms. Gynecol Oncol 69:210-213, 1998.
40. Allen HJ, DiCioccio RA, Hohmann P, et al: Microsatellite instability in ovarian and other pelvic carcinomas. Cancer Genet Cytogenet 117:163-166, 2000.
41. Mok SC, Bell DA, Knapp RC, et al: Mutation of K-ras pro-tooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489-1492, 1993.
42. Ichikawa Y, Nishida M, Suzuki H: Mutation of KRAS protoon-cogene is associated with histological subtypes in human muci-nous ovarian tumors. Cancer Res 54:33-35, 1994.
43. Enomoto T, Weghorst CM, Inoue M, et al: K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777-785, 1991.
44. Gemignani ML, Schlaerth AC, Bogomolniy F, et al: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gyncol Oncol 90:378-381, 2003.
45. Wu R, Zhai Y, Fearon ER, et al: Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61:8247-8255, 2001.
46. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al: Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10:116122, 2001.
47. Obata K, Morland SJ, Watson RH, et al: Frequent PTEN/ MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095-2097, 1998.
48. Sato N, Tsunoda H, Nishida M, et al: Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052-7056, 2000.
49. Saito M, Okamoto A, Kohno T, et al: Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85:160-165, 2000.
50. Thomas EJ, Campbell IG: Molecular genetic defects in endome-triosis. Gynecol Obstet Invest 50:44-50, 2000.
51. Obata K, Hoshiai H: Common genetic changes between endo-metriosis and ovarian cancer. Gynecol Obstet Invest 50:39-43, 2000.
52. Bischoff FZ, Simpson JL: Heritability and molecular genetic studies of endometriosis. Hum Reprod Update 6:37-44, 2000.
53. Dinulescu DM, Ince TA, Quade BJ, et al: Role of K-ras and Pten in the development of mouse models of endometriosis and endo-metrioid ovarian cancer. Nat Med 11:63-70, 2005.
54. Wu R, Hendrix-Lucas N, Kuick R, et al: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321-333, 2007.
55. Tsuchiya A, Sakamoto M, Yasuda J, et al: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-lbeta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503-2512, 2003.
56. Hough CD, Sherman-Baust CA, Pizer ES, et al: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60:6281-6287, 2000.
57. Franc is-Thickpenny KM, Richardson DM, van Ee CC, et al: Analysis of the TGF-beta functional pathway in epithelial ovarian carcinoma. Br J Cancer 85:687-691, 2001.
58. Fujita M, Enomoto T, Yoshino K, et al: Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64:361-366, 1995.
59. Gras E, Catasus L, Arguelles R, et al: Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92:2829-2836, 2001.
60. Druker BJ: Perspectives on the development of a molecularly targeted agent. Cancer Cell 1:31-36, 2002.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.